

The Frequency of Exotoxin A and Exoenzymes S and U Genes Among Clinical Isolates of *Pseudomonas aeruginosa* in Shiraz, Iran

Arshid Yousefi-Avarvand¹, Reza Khashei^{1*}, Hadi Sedigh Ebrahim-Saraie¹, Amir Emami¹,
Kamiar Zomorodian², Mohammad Motamedifar^{1,3}

1. Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
2. Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
3. Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Submitted 5 June 2015; Accepted 25 July 2015; Published 25 August 2015

Pseudomonas aeruginosa as an opportunistic pathogen produces several virulence factors. The most important of these factors are exotoxin A and type III secretion system (T3SS). The aim of this study was to determine the frequency of *toxA*, *exoU* and *exoS* genes among clinical isolates of *P. aeruginosa*. In this cross-sectional study from September 2011 to February 2012, 156 *P. aeruginosa* isolates were recovered from different clinical samples. Susceptibility testing against 10 antibiotics was performed on individual isolates by the disc diffusion method according to CLSI guidelines. Extracted DNA was subjected to PCR assay for determining the presence of *toxA*, *exoU* and *exoS* genes. Overall, the frequency of *toxA*, *exoU* and *exoS* genes were 90.4%, 66.7% and 65.4%, respectively. All of the abdominal and eye isolates were *exoS*⁺. The frequency of *exoS*⁺/*exoU*⁺ and *exoS*⁺/*exoU*⁻ genotypes was estimated 19.2% and 16.2%, respectively. Indeed, genotypes *exoS*⁺/*exoU*⁺ and *exoS*⁻/*exoU*⁺ were found with frequencies of 48.7% and 15.3%, respectively. The highest and lowest antibiotic resistance rate was seen against aztreonam (94.2%) and amikacin (44.9%), respectively. Fluoroquinolone-resistant isolates were isolated with frequency of 45.8%. Multi-drug resistant (MDR) isolates were detected in 62.8% of isolates. The resistance rate in *exoU*⁺ isolates was 86% compared to 66% in *exoS*⁺ isolates. The high frequencies of virulence genes detected in our clinical isolates with notable antibiotic resistance rates indicate the potential risk of these isolates in nosocomial infections.

Key words: *Pseudomonas aeruginosa*, exotoxin A, exoenzyme S, exoenzyme U

Pseudomonas aeruginosa is a Gram-negative and opportunistic pathogen which is widespread throughout the environment (1). In immune

competent hosts, the bacterium seldom causes disease (1, 2). *P. aeruginosa* causes a wide range of infections including septicemia, pneumonia, endo-

* Corresponding author: Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Zand St, Imam Hossein Sq, Shiraz, Iran. E-mail: khasheir@sums.ac.ir, re.khashei@gmail.com

carditis, burn wounds, otitis and keratitis. It is also frequently encountered in cystic fibrosis, immunocompromised and/or hospitalized individuals (3-5). The pathogenesis of *P. aeruginosa* is multifactorial and comprises several cell-associated and extracellular virulence determinants. These include exotoxin A (ExoA), phospholipase, elastase, pyocyanin, pili, flagella and lipopolysaccharide (3,6,7). Proliferation of *P. aeruginosa* in host cells and overcoming defense mechanisms is due to the transfer of many proteins via specialized secretion apparatuses including the types I,II,III,V and VI secretory systems (TSS) (2, 8).

ExoA is the major member of the type II secretion system (T2SS) which inhibits protein synthesis by ADP-ribosylation of eukaryotic elongation factor 2 (1, 8, 9). Another important virulence factor recently recognized is the type III secretion system (T3SS) (3, 6). T3SS is a contact-dependent protein secretion pathway that plays a major role in the pathogenesis of serious *P. aeruginosa* infections (10). The four well known T3SS effector molecules are exoenzymes (Exo) S, U, T and Y (2). It is known that these effectors are delivered to the host cells via a translocation complex consisting of products encoded by the *pcrGVHpopBD* operon that cause cell necrosis and modulation of actin cytoskeleton, allowing the bacteria to invade the eukaryotic cells and escape phagocytosis (3, 6, 10).

ExoS is a major cytotoxin involved in stages of colonization, invasion and dissemination of infection (11). ExoU is a potent cytotoxin with phospholipase activity, capable of killing a variety of eukaryotic cells *in vitro* (12, 13). Additionally, ExoU has a greater effect than other T3SS effectors on the virulence of the bacteria (10).

A key determinant of *P. aeruginosa* is its remarkable resistance to antibiotics and notably many of isolates are multidrug-resistant (MDR) (14). In several studies, the relationship between MDR isolates and presence of genes encoding

T3SS, especially ExoU has been demonstrated (10, 14).

As the presence of T3SS encoding genes in clinical isolates of *P. aeruginosa* is a variable trait, distribution of these genes in different populations should be explored. Moreover, to the best of the authors' knowledge there is no previous report from Shiraz investigating the prevalence of *P. aeruginosa* virulence genes. Therefore, the present study aimed to evaluate the frequencies of *tox*A, *exo*S and *exo*U genes among the different clinical isolates of *P. aeruginosa*. We also sought to determine whether there is any correlation between the presence of these genes and antibiotic resistance profile of the isolates.

Materials and methods

Study design and clinical specimens

In this cross-sectional study, a total 156 *P. aeruginosa* clinical isolates were obtained from September 2011 to February 2012 in Shiraz (a major city in the south of Iran) teaching hospitals. The samples included: urine, cerebrospinal fluid (CSF), sputum, abdominal discharge (AD), endotracheal tube aspirates (ETT), eye, blood, and wound.

Bacterial identification

All the isolates were identified as *P. aeruginosa* using both the conventional microbiologic (e.g., Gram staining, capacity for growth at 42 °C, oxidase, and IMViC tests) methods and Microgen™ GnA+B-ID System (Microgen Bioproducts Ltd, U.K) diagnostic kit. Confirmed *P. aeruginosa* isolates were stored in tryptic soy broth (TSB) (Merck Co., Germany) containing 20% glycerol at -70 °C until further study.

Antibiotic susceptibility testing

The antimicrobial susceptibility test was done by disk diffusion method on Muller-Hinton agar (Merck Co., Germany). The following antibiotics were tested: Ceftazidime (30 µg), Aztreonam (30 µg), Gentamicin (10 µg), Piperacillin+Tazobactam (110 µg), Amikacin (30 µg), Ticarcillin (75 µg),

Ciprofloxacin (5 µg), Imipenem (10 µg), Ofloxacin (30 µg) and Meropenem (10 µg) (MAST Co., U.K), in accordance with clinical and laboratory standards institute (CLSI) recommendations (15). MDR isolates were defined if they showed simultaneous resistance to ≥ 3 antibiotics. The *P. aeruginosa* ATCC 27853 was used as a reference strain for the quality control of susceptibility test. The intermediate isolates were accounted as resistant in our results.

Genomic DNA purification and molecular assay

Genomic DNA was extracted from overnight TSB cultures of *P. aeruginosa* isolates using the small-scale phenol-chloroform extraction method (16). The evaluation of *toxA*, *exoS* and *exoU* genes was accomplished by previously described primers (9,17). PCR amplification was performed in 50 µl reaction volume consisting of 5 µl 1x PCR buffer, 2 µl of each primer (10 pmol/µl), 1 µl MgCl₂ (1.5 mM), 0.8 µl each of the dNTPs (200 µM), 0.6 µl Taq DNA polymerase (1 U), and 2 µl DNA (10-1,000 ng) from each isolate. The PCR cycling conditions were: initial denaturation at 95 °C for 10 min, followed by 30 cycles (for *exoA* gene) and 35

cycles (for *exoU* and *exoS* genes) of denaturation at 95 °C for 30 seconds, annealing at 55 °C for 45 seconds, extension at 72 °C for 40 seconds, with final extension at 72 °C for 10 min. All reagents were obtained from Cinnagene Co., Iran. In each run of amplicons, *P. aeruginosa* ATCC 27853 which is positive for both *toxA* and *exoS*, and one clinical isolate which became positive for the presence of *exoU* gene (428 bp amplicon) and was further confirmed by DNA sequencing, and negative (*E. coli* ATCC 35218) controls were included in agarose gels. The amplicons were resolved in a 1% horizontal agarose gel, stained with ethidium bromide and photographed under 300 nm UV light (Figure 1).

Statistical analyzes

Statistical analyses were performed using SPSSTM software, version 21.0. The results for antimicrobial susceptibility and the current genes were presented as descriptive statistics in terms of relative frequencies. Chi-square test or Fisher's exact test was used to analyze the results wherever needed and a p-value < 0.05 was considered as significant clinical relevance.




Fig. 1. Amplification of *toxA*, *exoS* and *exoU* genes from clinical isolates of *P. aeruginosa* by PCR. M: 100 bp ladder; lane 1: *toxA* gene positive control; lanes 2, 8 and 15: negative control (*E. coli* ATCC 35218); lanes 3-6 investigated clinical isolates for *toxA* gene; lane 7: *exoU* gene positive control; lanes 9-12: investigated clinical isolates for *exoU* gene; lane 14: *exoS* gene positive control; lanes 16-18: investigated clinical isolates for *exoS* gene.

Table 1. Antibiotic susceptibility profile of *P. aeruginosa* isolates based on source of isolation

| Antibiotic Specimen | CAZ No. (%) | IMI No. (%) | OFX No. (%) | GM No. (%) | PTZ No. (%) | TC No. (%) | MER No. (%) | CIP No. (%) | AZT No. (%) | AK No. (%) |
|---------------------|-------------|-------------|-------------|------------|-------------|------------|-------------|-------------|-------------|------------|
| Urine (57) | 21 (37) | 37 (65) | 28 (49) | 30 (53) | 16 (28) | 15 (26) | 32 (56) | 30 (53) | 3 (5.3) | 37 (65) |
| CSF (4) | 3 (75) | 4 (100) | 3 (75) | 3 (75) | 2 (50) | 2 (50) | 4 (100) | 3 (75) | 1 (25) | 4 (100) |
| Sputum (35) | 10 (29) | 19 (54) | 14 (40) | 16 (46) | 5 (14) | 7 (20) | 18 (51) | 19 (54) | 2 (5.7) | 16 (46) |
| Abdominal (4) | 1 (25) | 3 (75) | 1 (25) | 3 (75) | 0 | 1 (25) | 3 (75) | 3 (75) | 0 | 3 (75) |
| ETT (19) | 5 (26) | 11 (58) | 9 (47) | 11 (58) | 6 (32) | 5 (26) | 10 (53) | 10 (53) | 2 (11) | 12 (63) |
| Eye (5) | 2 (40) | 1 (20) | 1 (20) | 2 (40) | 1 (20) | 0 | 3 (60) | 3 (60) | 0 | 3 (60) |
| Blood (3) | 3 (100) | 2 (67) | 2 (67) | 2 (67) | 2 (67) | 2 (67) | 2 (67) | 2 (67) | 0 | 2 (67) |
| Wound (29) | 7 (24) | 7 (24) | 6 (21) | 5 (17) | 4 (14) | 1 (3.4) | 8 (28) | 6 (21) | 1 (3.4) | 9 (67) |
| Total (156) | 52 (33.3) | 84 (53.8) | 64 (41) | 72 (46.2) | 36 (23.1) | 33 (21.2) | 80 (51.3) | 76 (42.9) | 9 (5.8) | 86 (55.1) |

CAZ: Cefotaxime; IMI: Imipenem; OFX: Ofloxacin, GM: Gentamycin; PTZ: Piperacillin/ tazobactam; TC: Ticarcillin; MER: Meropenem; CIP: Ciprofloxacin; AZT: Aztreonam; AK: Amikacin.

Table 2. Distribution of *P. aeruginosa* isolates virulence genes based on source of isolation.

| Genes Specimen | <i>toxA</i> No. (%) | <i>exoS</i> ^b No. (%) | <i>exoU</i> ^b No. (%) |
|-----------------------------|---------------------|----------------------------------|----------------------------------|
| Urine (57) ^{c,d} | 49 (86.0) | 32 (56.1) | 33 (57.9) |
| CSF (4) | 2 (50.0) | 3 (75.0) | 2 (50.0) |
| Sputum (35) | 30 (85.7) | 24 (68.6) | 23 (65.7) |
| Abdominal (4) | 4 (100.0) | 4 (100.0) | 2 (50.0) |
| ETT (19) ^{c,d} | 19 (100.0) | 14 (73.7) | 14 (73.7) |
| Eye (5) | 5 (100.0) | 5 (100.0) | 4 (80.0) |
| Blood (3) | 3 (100.0) | 1 (33.3) | 2 (66.7) |
| Wound (29) ^{a,c,d} | 29 (100.0) | 21 (72.4) | 22 (75.9) |
| Total | 141 (90.4) | 104 (66.7) | 102 (65.4) |

^a Frequency of *toxA* among wound samples was significantly higher than urine isolates ($P < 0.05$) and distribution of *toxA* among other sources was not significantly different. ^b Distribution of *exoS* and *exoU* among clinical samples showed no significant differences. ^c Significant differences of *toxA* frequency compared to *exoS* among individuals clinical samples ($P < 0.05$). ^d Significant differences of *toxA* frequency compared to *exoU* among individuals clinical samples ($P < 0.05$).

Results

Of the total 156 *P. aeruginosa* isolates, majority of isolates were recovered from urine (n= 57) and sputum (n= 35) specimens (Table 1). The results of antibiotic susceptibility revealed that tested *P. aeruginosa* isolates were mostly sensitive to amikacin (55.1%), imipenem (53.8%) and meropenem (51.3%). On the other hand, the most resistance rates were seen against aztreonam (94.2%), ticarcillin (78.8%) and piperacillin /tazobactam (76.9%). The results of antibiotic

susceptibility profile for *P. aeruginosa* isolates were summarized in Table 1. Moreover, among the 156 isolates, 98 (62.8%) were MDR.

The presence of *toxA*, *exoS* and *exoU* genes was detected in 90.4%, 66.7% and 65.4% of all the isolates, respectively. The distribution of virulence genes among different clinical samples is shown in Table 2. The *toxA* and *exoS* were detected among all the isolates from AD and eye samples. However, the relative frequency of *exoU* was higher in the eye (80%) and wound (75.9%) compared to that seen in

other clinical samples. Although, relative frequencies of virulence genes were different between clinical specimens, statistical analysis showed no differences for the presence of individual genes and source of isolation. The only exception was *toxA* which was significantly ($P < 0.05$) higher among wound isolates (29/29) compared to urine ones (49/57). Moreover, isolates recovered from urine, wound and ETT samples contained significantly ($P < 0.001$) a higher frequency of *toxA* gene than *exoS* and *exoU*. The frequency of *exoS*⁺/*exoU*⁻, *exoS*⁻/*exoU*⁺, *exoS*⁺/*exoU*⁺ and *exoS*⁻/*exoU*⁻ genotypes were 19.2%, 16.2%, 48.7% and 15.3%, respectively.

The *exoA*⁺, *exoS*⁺ and *exoU*⁺ genotypes demonstrated a higher spread (96.9%, 67.3% and 72.4%, respectively) among MDR than non-MDR isolates ($P < 0.05$). Indeed, resistance to aztreonam (74.4%) was mainly associated to the isolates harboring *exoA* in comparison to other genes ($P < 0.05$).

Discussion

As detection of virulence genes in clinical isolates of *P. aeruginosa* is important (3,18), thus, in the present study, the frequency of some *P. aeruginosa* virulence genes among different clinical isolates was characterized. As among T3SS, *exoT* and *pcrV* (part of the injection apparatus of the T3SS) genes exist in nearly all *P. aeruginosa* isolates from both clinical and environmental origins (3,12,19), the presence of these genes was not evaluated in this study.

In our investigation, 100% of *P. aeruginosa* isolates from the AD, ET, eye, blood and wound samples were *toxA*⁺. The *exoS* gene was also detected in 100% of isolates from the AD and eye samples. According to our results, the relative frequencies of virulence genes were higher in some special clinical specimens. It has been suggested that the infection site and duration of disease

influences the virulence of *P. aeruginosa* clinical isolates by altering the production of some virulence determinants. For example, some anatomical sites enhance the production of ExoA and ExoS (10).

In a research in Poland by Wolska et al., the prevalence of *toxA* among the 62 clinical isolates of *P. aeruginosa* was 88.7%, which is comparable with our study. However, the frequency of *exoS* was more than that of the present study (75.8% vs. 66.7%) (17). It seems that the *exoU* had been acquired through a mobile element (plasmid) integrated into the chromosome of *P. aeruginosa*. Therefore, the lower prevalence of the gene than the other virulence genes could be due to this phenomenon (11). However, in our analysis, this rate was nearly the same as *exoS* prevalence (65.4% vs. 66.7%). In the study conducted by Mitove et al. (20) on 202 cystic fibrosis (CF) and non-CF patients, the frequency of *exoS* was 62.4%, whereas the prevalence of *exoU* was found to be 30.2%, which is not in agreement with our study. Interestingly, in a survey in France, the prevalence of *exoS* was markedly higher than other studies (94% in CF isolates vs. 80% in non-CF isolates) (21).

Wareham et al. showed a significant correlation between the distribution of *exoS*⁺/*exoU*⁻ and *exoS*⁻/*exoU*⁺ genotypes with CF (sputum sample) and blood isolates, respectively, which is in concordance with our results (13). Likewise, these results are reported by Feltman et al., who had established an association between *exoS*⁺/*exoU*⁺ genotype with CF isolates (6). In another work by Wong-Beringer et al. *exoS*⁺/*exoU*⁻ (9%) and *exoS*⁻/*exoU*⁻ (2%) genotypes were found among 45 clinical isolates of *P. aeruginosa* (14). Moreover, in a study conducted on 55 keratitis isolates, 64% of isolates contained *exoS*⁺/*exoU*⁻ genotype, whereas 33% and 4% were *exoS*⁻/*exoU*⁺, and *exoS*⁺/*exoU*⁺, respectively (18).

It is generally suggested that isolates from clinical setting contain either *exoS* or *exoU* gene but not both (22). However, interestingly, in our analysis, 48.7% and 15.3% of the isolates had *exoS*⁺/*exoU*⁺ and *exoS*⁻/*exoU* genotypes, respectively. Similar to our survey, in the study of Finnan et al., 75% of isolates were *exoS*⁺/*exoU*⁺ (23).

Our results showed that the overall resistance to aztreonam (94.2%) and ticarcillin (78.8%) was remarkably high. Among clinical specimens, AD and eye isolates were 100% resistant to aztreonam. Furthermore, isolates from CSF samples were not resistant to 6 antibiotics of 10 tested antimicrobial agents. But the isolates obtained from other clinical samples showed resistance (with different rates) to all antibiotics. The lowest resistance was seen against amikacin (44.9%), which seems to be the *in vitro* drug of choice in our investigation.

Fluoroquinolones such as ciprofloxacin and levofloxacin have a great potency *in vitro* on *P. aeruginosa*; however, because of the widespread usage of these agents, resistance to them has developed (10). In the present study, the overall resistance to ciprofloxacin and ofloxacin were 43.6% and 48.1%, respectively. In contrast to our results, in the study of Choy et al., resistance to fluoroquinolones was found to be 11%. However, this resistance was only related to ofloxacin, whereas all isolates of *P. aeruginosa* were sensitive to ciprofloxacin (18). A relatively high resistance was cited by Agnello et al. with 54% of pneumonic isolates of *P. aeruginosa* being resistant to levofloxacin (10).

On the other hand, in our investigation 62.8% of the resistant isolates exhibited MDR phenotype. The MDR results, is nearly consistent with the finding of a study in Bulgaria with 57.5% prevalence (20). It has been suggested that the clinical isolates comprising *exoU* gene were significantly associated with MDR phenotype (18). This finding is supported in our results, since MDR resistance rate in *exoU*⁺ isolates with 80%

frequency was higher compared to 66% in *exoS*⁺ isolates. The prevalence of such high resistant *P. aeruginosa* in our region is not uncommon, since, previously Anvarinejad et al. and Sarhangi et al. showed high rate of MDR among isolates from the burn patients and clinical isolates from Shiraz City, respectively (24, 25).

One of the limitations of this study was the small sample size of specimens such as blood, CSF, which could affect the results. However, beside the limitations, the current study has some outcomes. First we showed a relatively high frequency of *tox*A, *exoS* and *exoU* genes among *P. aeruginosa* clinical isolates obtained in our area and this frequency was associated to high antibiotic resistance among the isolates. Second, it seems that the source of bacterial isolation is associated with the trend of acquisition of specific virulence genes and these genes may serve to cause specific infections. These results indicate the potential risk of these isolates in nosocomial infections which merit more attention. Of course, further studies are required with larger sample size and from other regions of country to reach a comprehensive conclusion.

Acknowledgment

The present article was extracted from the M.Sc thesis of Ms. Arshid Yousefi Avarvand and was financially supported by Shiraz University of Medical Sciences, grant number 91-6039.

Conflict of interests

The authors declared no conflict of interests.

References

1. Rumbaugh KP, Hamood AN, Griswold JA. Analysis of *Pseudomonas aeruginosa* clinical isolates for possible variations within the virulence genes exotoxin A and exoenzyme S. J Surg Res 1999;82:95-105.
2. Engel J, Balachandran P. Role of *Pseudomonas aeruginosa* type III effectors in disease. Curr Opin Microbiol 2009;12:61-6.
3. Berthelot P, Attree I, Plesiat P, et al. Genotypic and phenotypic analysis of type III secretion system in a cohort of

Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association between O serotypes and exo genes. J Infect Dis 2003;188:512-8.

4. Nikokar I, Tishayar A, Flakiyan Z, et al. Antibiotic resistance and frequency of class 1 integrons among *Pseudomonas aeruginosa*, isolated from burn patients in Guilan, Iran. Iran J Microbiol 2013;5:36-41.

5. Lavenir R, Jocktane D, Laurent F, et al. Improved reliability of *Pseudomonas aeruginosa* PCR detection by the use of the species-specific *ecfX* gene target. J Microbiol Methods 2007;70:20-9.

6. Feltman H, Schultert G, Khan S, et al. Prevalence of type III secretion genes in clinical and environmental isolates of *Pseudomonas aeruginosa*. Microbiology 2001;147:2659-69.

7. Faezi S, Safarloo M, Amirmozafari N, et al. Protective efficacy of *Pseudomonas aeruginosa* type-A flagellin in the murine burn wound model of infection. APMIS 2014;122:115-27.

8. Lee VT, Smith RS, Tummler B, et al. Activities of *Pseudomonas aeruginosa* effectors secreted by the Type III secretion system in vitro and during infection. Infect Immun 2005;73:1695-705.

9. Kaszab E, Szoboszlay S, Dobolyi C, et al. Antibiotic resistance profiles and virulence markers of *Pseudomonas aeruginosa* strains isolated from composts. Bioresour Technol 2011;102:1543-8.

10. Agnello M, Wong-Beringer A. Differentiation in quinolone resistance by virulence genotype in *Pseudomonas aeruginosa*. PLoS One 2012;7:e42973.

11. Bradbury RS, Roddam LF, Merritt A, et al. Virulence gene distribution in clinical, nosocomial and environmental isolates of *Pseudomonas aeruginosa*. J Med Microbiol 2010;59:881-90.

12. Jain M, Ramirez D, Seshadri R, et al. Type III secretion phenotypes of *Pseudomonas aeruginosa* strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004;42:5229-37.

13. Wareham DW, Curtis MA. A genotypic and phenotypic comparison of type III secretion profiles of *Pseudomonas aeruginosa* cystic fibrosis and bacteremia isolates. Int J Med Microbiol 2007;297:227-34.

14. Wong-Beringer A, Wiener-Kronish J, Lynch S, et al. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of *Pseudomonas aeruginosa*. Clin Microbiol Infect 2008;14:330-6.

15. performance standards for antimicrobial susceptibility testing, 12th edition. Clinical and Laboratory Standard Institute (CLSI). 2010.

16. Sambrook J, Russell DW. Purification of nucleic acids by extraction with phenol:chloroform. CSH Protoc 2006;2006.

17. Wolska K, Szveda P. Genetic features of clinical *Pseudomonas aeruginosa* strains. Pol J Microbiol 2009;58:255-60.

18. Choy MH, Stapleton F, Willcox MD, et al. Comparison of virulence factors in *Pseudomonas aeruginosa* strains isolated from contact lens- and non-contact lens-related keratitis. J Med Microbiol 2008;57:1539-46.

19. Schultert GS, Feltman H, Rabin SD, et al. Secretion of the toxin ExoU is a marker for highly virulent *Pseudomonas aeruginosa* isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 2003;188:1695-706.

20. Mitov I, Strateva T, Markova B. Prevalence of virulence genes among bulgarian nosocomial and cystic fibrosis isolates of *pseudomonas aeruginosa*. Braz J Microbiol 2010;41:588-95.

21. Lanotte P, Watt S, Mereghetti L, et al. Genetic features of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients compared with those of isolates from other origins. J Med Microbiol 2004;53:73-81.

22. Sato H, Frank DW. ExoU is a potent intracellular phospholipase. Mol Microbiol 2004;53:1279-90.

23. Finnan S, Morrissey JP, O'Gara F, et al. Genome diversity of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients and the hospital environment. J Clin Microbiol 2004;42:5783-92.

24. Anvarinejad M, Japoni A, Rafatpour N, et al. Burn Patients Infected With Metallo-Beta-Lactamase-Producing *Pseudomonas aeruginosa*: Multidrug-Resistant Strains. Arch Trauma Res 2014;3:e18182.

25. Sarhangi M, Motamedifar M, Sarvari J. Dissemination of *Pseudomonas aeruginosa* producing blaIMP1, blaVIM2, blaSIM1, blaSPM1 in Shiraz, Iran Jundishapur J Microbiol 2013;3:e6920.